100 related articles for article (PubMed ID: 27366889)
1. AAV9 Delivery of shRNA to the Mouse Heart.
Wakimoto H; Seidman JG; Foo RSY; Jiang J
Curr Protoc Mol Biol; 2016 Jul; 115():23.16.1-23.16.9. PubMed ID: 27366889
[TBL] [Abstract][Full Text] [Related]
2. Intraperitoneal AAV9-shRNA inhibits target expression in neonatal skeletal and cardiac muscles.
Mayra A; Tomimitsu H; Kubodera T; Kobayashi M; Piao W; Sunaga F; Hirai Y; Shimada T; Mizusawa H; Yokota T
Biochem Biophys Res Commun; 2011 Feb; 405(2):204-9. PubMed ID: 21219850
[TBL] [Abstract][Full Text] [Related]
3. Design of AAV Vectors for Delivery of RNAi.
Borel F; Mueller C
Methods Mol Biol; 2019; 1950():3-18. PubMed ID: 30783965
[TBL] [Abstract][Full Text] [Related]
4. Systemic delivery of shRNA by AAV9 provides highly efficient knockdown of ubiquitously expressed GFP in mouse heart, but not liver.
Piras BA; O'Connor DM; French BA
PLoS One; 2013; 8(9):e75894. PubMed ID: 24086659
[TBL] [Abstract][Full Text] [Related]
5. AAV Vectors for Efficient Gene Delivery to Rodent Hearts.
Lopez-Gordo E; Kohlbrenner E; Katz MG; Weber T
Methods Mol Biol; 2019; 1950():311-332. PubMed ID: 30783983
[TBL] [Abstract][Full Text] [Related]
6. Development of an AAV9-RNAi-mediated silencing strategy to abrogate TRPM4 expression in the adult heart.
Medert R; Jungmann A; Hildebrand S; Busch M; Grimm D; Flockerzi V; Müller OJ; Most P; Schumacher D; Freichel M
Pflugers Arch; 2021 Mar; 473(3):533-546. PubMed ID: 33580817
[TBL] [Abstract][Full Text] [Related]
7. Efficient Gene Suppression in Dorsal Root Ganglia and Spinal Cord Using Adeno-Associated Virus Vectors Encoding Short-Hairpin RNA.
Enomoto M; Hirai T; Kaburagi H; Yokota T
Methods Mol Biol; 2016; 1364():277-90. PubMed ID: 26472458
[TBL] [Abstract][Full Text] [Related]
8. Cardiac-targeted RNA interference mediated by an AAV9 vector improves cardiac function in coxsackievirus B3 cardiomyopathy.
Fechner H; Sipo I; Westermann D; Pinkert S; Wang X; Suckau L; Kurreck J; Zeichhardt H; Müller O; Vetter R; Erdmann V; Tschope C; Poller W
J Mol Med (Berl); 2008 Sep; 86(9):987-97. PubMed ID: 18548221
[TBL] [Abstract][Full Text] [Related]
9. TransKingdom RNA interference: a bacterial approach to challenges in RNAi therapy and delivery.
Keates AC; Fruehauf J; Xiang S; Li CJ
Biotechnol Genet Eng Rev; 2008; 25():113-27. PubMed ID: 21412352
[TBL] [Abstract][Full Text] [Related]
10. Design of shRNA and miRNA for Delivery to the CNS.
Toro Cabrera G; Mueller C
Methods Mol Biol; 2016; 1382():67-80. PubMed ID: 26611579
[TBL] [Abstract][Full Text] [Related]
11. Suppression of transforming growth factor β1 in lung alveolar epithelium-derived cells using adeno-associated virus type 2/5 vectors to carry short hairpin RNA.
Kage H; Sugimoto K; Sano A; Kitagawa H; Nagase T; Ohishi N; Takai D
Exp Lung Res; 2011 Apr; 37(3):175-85. PubMed ID: 21269064
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of AAV-mediated delivery of shRNA to target basal-like breast cancer genetic vulnerabilities.
Pinto C; Silva G; Ribeiro AS; Oliveira M; Garrido M; Bandeira VS; Nascimento A; Coroadinha AS; Peixoto C; Barbas A; Paredes J; Brito C; Alves PM
J Biotechnol; 2019 Jul; 300():70-77. PubMed ID: 31150679
[TBL] [Abstract][Full Text] [Related]
13. A Calsequestrin Cis-Regulatory Motif Coupled to a Cardiac Troponin T Promoter Improves Cardiac Adeno-Associated Virus Serotype 9 Transduction Specificity.
Chamberlain K; Riyad JM; Garnett T; Kohlbrenner E; Mookerjee A; Elmastour F; Benard L; Chen J; VandenDriessche T; Chuah MK; Marian AJ; Hajjar RJ; Gurha P; Weber T
Hum Gene Ther; 2018 Aug; 29(8):927-937. PubMed ID: 29641321
[TBL] [Abstract][Full Text] [Related]
14. Intraperitoneal administration of AAV9-shRNA inhibits target gene expression in the dorsal root ganglia of neonatal mice.
Machida A; Kuwahara H; Mayra A; Kubodera T; Hirai T; Sunaga F; Tajiri M; Hirai Y; Shimada T; Mizusawa H; Yokota T
Mol Pain; 2013 Jul; 9():36. PubMed ID: 23866078
[TBL] [Abstract][Full Text] [Related]
15. Preparation of rAAV9 to Overexpress or Knockdown Genes in Mouse Hearts.
Ding J; Lin ZQ; Jiang JM; Seidman CE; Seidman JG; Pu WT; Wang DZ
J Vis Exp; 2016 Dec; (118):. PubMed ID: 28060283
[TBL] [Abstract][Full Text] [Related]
16. Alleviation of off-target effects from vector-encoded shRNAs via codelivered RNA decoys.
Mockenhaupt S; Grosse S; Rupp D; Bartenschlager R; Grimm D
Proc Natl Acad Sci U S A; 2015 Jul; 112(30):E4007-16. PubMed ID: 26170322
[TBL] [Abstract][Full Text] [Related]
17. Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain.
Deverman BE; Pravdo PL; Simpson BP; Kumar SR; Chan KY; Banerjee A; Wu WL; Yang B; Huber N; Pasca SP; Gradinaru V
Nat Biotechnol; 2016 Feb; 34(2):204-9. PubMed ID: 26829320
[TBL] [Abstract][Full Text] [Related]
18. AAV Gene Transfer to the Heart.
Wang S; Guo Y; Pu WT
Methods Mol Biol; 2021; 2158():269-280. PubMed ID: 32857380
[TBL] [Abstract][Full Text] [Related]
19. Intravascular AAV9 Administration for Delivering RNA Silencing Constructs to the CNS and Periphery.
Dufour BD; McBride JL
Methods Mol Biol; 2016; 1364():261-75. PubMed ID: 26472457
[TBL] [Abstract][Full Text] [Related]
20. AAV delivery of mineralocorticoid receptor shRNA prevents progression of cold-induced hypertension and attenuates renal damage.
Wang X; Skelley L; Cade R; Sun Z
Gene Ther; 2006 Jul; 13(14):1097-103. PubMed ID: 16554840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
